We are developing
A single platform for defeating cancer and much more.
fail to respond to immunotherapy have run out of therapeutic options
A single platform for defeating cancer
We are HEPHAISTOS-Pharma

Scientific Founders
Team
Board Members
Scientific Advisory Board
Approach
Turning cold tumors into hot tumors

Only 10% of current immunotherapies are successful
Need for stronger and safer immuno-modulators
to turn cold tumors into hot tumors and improve cancer therapy
Innovation & advantages
Onco-Boost platform
ONCO-Boost is the First-In-Class Immunostimulant injectable intravenously, able to treat metastatic and hardly accessible cancer like Osteorsarcoma

Mechanism of Action
Mechanism of Action (MoA)

ONCO-Boost
will stimulate monocytes, and dendritic cells to recruit and mature other immune defenses like CD4 T Cells, CD8 T Cells and macrophages.
Monoclonal
Antibody (mAb)
will block friendly recognition pathways between Tumor cells and host Cells allowing immune defenses to see Tumors as targets to destroy.
All together
By recruiting and stimulating immune cells, ONCO-Boost enables the treatment of tumors that were not previously sensitive to mAb’s action and opens the way to treat incurable cancers.
Publications
Pipeline
News
“Golden Ticket” award for HEPHAISTOS from Amgen France and BioLabs Hôtel-Dieu
December 10th, 2024 HEPHAISTOS-Pharma has the honor to…
HEPHAISTOS laureate of the HACKATHON against childhood cancer
November 22th, 2024 HEPHAISTOS-Pharma was laureate of the…
HEPHAISTOS secures €10.3 M to reach the clinical stage
HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round,…
Frederic CAROFF will attend BIO Europe Spring in Barcelona
Our CEO, Frederic CAROFF will be attending BIO-Europe…
Media coverage
25 January 2024
02 November 2020
Clusters & Partners






Financial Supports

HEPHAISTOS-Pharma has received funding from ANR (#ANR-23-RHUS-0003) and received State support through France 2030 program.

HEPHAISTOS-Pharma has received funding from the European Union – Next Generation EU through the program France Relance.

HEPHAISTOS-Pharma has received funding from the European Union EIC Accelerator program

HEPHAISTOS-Pharma has received funding from the European Union FEDER regional fund

HEPHAISTOS-Pharma has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 868937

HEPHAISTOS-Pharma’s academic partner CRCL has received funding from the Region Auvergne-Rhône-Alpes, the Grand Lyon Metropole and the CLARA Canceropole.

HEPHAISTOS-Pharma received financial support from WILCO Healthcare startup cluster.